NCT02944357View on ClinicalTrials.gov

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

September 5, 2017

Study Completion Date

September 5, 2017

Conditions
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

PROCEDURE

Radical Cystectomy

Undergo cystectomy

BIOLOGICAL

Tumor Cell-Derived Vaccine Therapy

Given AGS-003-BLD ID

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT02944357 - Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery | Biotech Hunter | Biotech Hunter